Sponsored by:

Molecular Imaging: Page 295

FLT-PET helps predicts cancer therapy results
By AuntMinnie.com staff writers
PET imaging with F-18 fluorothymidine (FLT) during treatment and early follow-up could predict therapeutic response and identify patients who need close follow-up to detect persistent or recurring head and neck squamous cell carcinomas, according to a study published in the October issue of the Journal of Nuclear Medicine.
October 1, 2012
Juweid reaches deal with Iowa medical board
By AuntMinnie.com staff writers
Former University of Iowa professor and nuclear medicine physician Dr. Malik Juweid has reached an agreement with the Iowa Board of Medicine to no longer practice in the state.
September 27, 2012
Indonesian nuclear medicine firm plans U.S. venture
By AuntMinnie.com staff writers
Indonesian nuclear technology firm Batan Teknologi (BatanTek) has unveiled plans to build a nuclear medicine facility in the U.S. by 2013 to produce radioisotopes for the U.S. market.
September 26, 2012
Molecular Insight launches phase II trial
By AuntMinnie.com staff writers
Radiopharmaceutical developer Molecular Insight Pharmaceuticals has begun a phase II clinical trial of its technetium-99m MIP-1404 prostate cancer molecular imaging agent.
September 26, 2012
Nuclear medicine pioneer Dr. Henry Wagner passes away
By Wayne Forrest
Dr. Henry Wagner Jr., a pioneer in the field of nuclear medicine and past president of the Society of Nuclear Medicine and Molecular Imaging, died on September 25 at the age of 85. Wagner is credited as being one of the founders of nuclear medicine as a scientific and medical specialty.
September 25, 2012
2012 09 26 11 30 40 286 Wagner 2006 06 04 Thumb
South Africa, Australia sign Mo-99 deal
By AuntMinnie.com staff writers
South Africa and Australia have formed a partnership for the supply of molybdenum-99 (Mo-99).
September 25, 2012
Carestream to sell preclinical imaging unit to Bruker
By AuntMinnie.com staff writers
Carestream Health has signed an agreement to sell the preclinical in vivo imaging equipment product portfolio and related assets from its Molecular Imaging business to Bruker.
September 20, 2012
Navidea gets NCI grant for RIGS agent
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals has received a grant from the U.S. National Cancer Institute (NCI) to develop a radioimmunoguided surgery (RIGS) agent for use in detecting metastatic sites in colorectal cancer.
September 20, 2012
PharmaRx suit against GE, Cardinal dismissed
By AuntMinnie.com staff writers
A federal judge in California has dismissed an antitrust suit filed by radiopharmacy PharmaRx Pharmaceutical against GE Healthcare and Cardinal Health, alleging the companies have a monopoly on sales of GE's Myoview cardiac imaging agent.
September 19, 2012
Australia to build Mo-99 facility
By AuntMinnie.com staff writers
The Australian government is allocating $168 million ($174 million U.S.) to build a nuclear medicine manufacturing plant to produce the medical isotope molybdenum-99 (Mo-99).
September 19, 2012
Navidea launches phase II trial
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceutical has enrolled the first patient in a phase II trial of its fluorine-18 NAV4694 radiopharmaceutical candidate, which is designed as an aid in detecting cerebral beta-amyloid plaque in subjects diagnosed with probable Alzheimer's disease.
September 17, 2012
NOPR asks CMS to ease coverage rules for PET
By AuntMinnie.com staff writers
The National Oncologic PET Registry (NOPR) is asking the U.S. Centers for Medicare and Medicaid Services (CMS) to make reimbursement for oncology PET studies easier by ending its requirement that payments be made under its coverage with evidence development (CED) statute.
September 16, 2012
Previous Page
Page 295 of 620
Next Page